Our observations provide mechanistic insights to explain the paucity of active MEK signaling in many RAS-dependent MM tumors7,8 and the underwhelming clinical response to MEK inhibitors in MM patients9,10. The gene discussed is MAP2K7; the disease is Miyoshi myopathy.